KR101322873B1 - 퀴놀리논 카르복사미드 화합물의 결정형 - Google Patents

퀴놀리논 카르복사미드 화합물의 결정형 Download PDF

Info

Publication number
KR101322873B1
KR101322873B1 KR1020077025632A KR20077025632A KR101322873B1 KR 101322873 B1 KR101322873 B1 KR 101322873B1 KR 1020077025632 A KR1020077025632 A KR 1020077025632A KR 20077025632 A KR20077025632 A KR 20077025632A KR 101322873 B1 KR101322873 B1 KR 101322873B1
Authority
KR
South Korea
Prior art keywords
crystalline
hydrochloride
oxo
isopropyl
dihydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077025632A
Other languages
English (en)
Korean (ko)
Other versions
KR20070116988A (ko
Inventor
폴 알. 패더리
에스. 데릭 터너
아담 골드블럼
로버트 차오
다니엘 제노브
Original Assignee
세라밴스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 인코포레이티드 filed Critical 세라밴스 인코포레이티드
Publication of KR20070116988A publication Critical patent/KR20070116988A/ko
Application granted granted Critical
Publication of KR101322873B1 publication Critical patent/KR101322873B1/ko
Assigned to 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 reassignment 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 권리의 전부이전등록 Assignors: 세라밴스 인코포레이티드
Assigned to 알파시그마 에스.피.에이. reassignment 알파시그마 에스.피.에이. 권리의 전부이전등록 Assignors: 세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077025632A 2005-04-06 2006-04-05 퀴놀리논 카르복사미드 화합물의 결정형 Expired - Lifetime KR101322873B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
KR20070116988A KR20070116988A (ko) 2007-12-11
KR101322873B1 true KR101322873B1 (ko) 2013-10-30

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077025632A Expired - Lifetime KR101322873B1 (ko) 2005-04-06 2006-04-05 퀴놀리논 카르복사미드 화합물의 결정형

Country Status (29)

Country Link
US (4) US7728004B2 (https=)
EP (1) EP1874766B1 (https=)
JP (2) JP5230407B2 (https=)
KR (1) KR101322873B1 (https=)
CN (1) CN101151264B (https=)
AR (2) AR053208A1 (https=)
AT (1) ATE479682T1 (https=)
AU (1) AU2006232129B2 (https=)
BR (1) BRPI0610657A2 (https=)
CA (1) CA2603654C (https=)
CY (1) CY1111275T1 (https=)
DE (1) DE602006016586D1 (https=)
DK (1) DK1874766T3 (https=)
EA (1) EA012115B1 (https=)
ES (1) ES2350495T3 (https=)
HR (1) HRP20100629T1 (https=)
IL (1) IL186023A (https=)
MA (1) MA29403B1 (https=)
MX (1) MX2007012438A (https=)
MY (1) MY151075A (https=)
NO (1) NO339699B1 (https=)
NZ (1) NZ561900A (https=)
PE (1) PE20061310A1 (https=)
PL (1) PL1874766T3 (https=)
PT (1) PT1874766E (https=)
SI (1) SI1874766T1 (https=)
TW (1) TWI377206B (https=)
WO (1) WO2006108127A2 (https=)
ZA (1) ZA200708071B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7399862B2 (en) * 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
EP2160188A2 (en) * 2007-05-17 2010-03-10 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
SMT201800036T1 (it) * 2009-04-13 2018-03-08 Theravance Biopharma R&D Ip Llc Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
KR102692887B1 (ko) * 2017-07-31 2024-08-08 알파시그마 에스.피.에이. 벨루세트라그를 사용하여 위마비 증상을 치료하는 방법
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
CA3263063A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. VELUSETRAG INTENDED FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
CN101163701A (zh) 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative

Also Published As

Publication number Publication date
PL1874766T3 (pl) 2011-02-28
CN101151264B (zh) 2011-07-06
AU2006232129A1 (en) 2006-10-12
MA29403B1 (fr) 2008-04-01
JP5230407B2 (ja) 2013-07-10
CN101151264A (zh) 2008-03-26
WO2006108127A3 (en) 2007-01-04
EA012115B1 (ru) 2009-08-28
IL186023A0 (en) 2008-01-20
EA200702161A1 (ru) 2008-04-28
US20060229332A1 (en) 2006-10-12
WO2006108127A2 (en) 2006-10-12
NO20075574L (no) 2007-11-02
JP2008535848A (ja) 2008-09-04
ZA200708071B (en) 2008-10-29
CA2603654C (en) 2014-05-27
SI1874766T1 (sl) 2010-12-31
AU2006232129B2 (en) 2012-07-12
CA2603654A1 (en) 2006-10-12
MX2007012438A (es) 2007-12-05
AR110019A2 (es) 2019-02-13
HRP20100629T1 (hr) 2010-12-31
CY1111275T1 (el) 2015-08-05
NO339699B1 (no) 2017-01-23
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
PE20061310A1 (es) 2007-01-23
IL186023A (en) 2011-09-27
TW200643020A (en) 2006-12-16
ATE479682T1 (de) 2010-09-15
DE602006016586D1 (de) 2010-10-14
NZ561900A (en) 2010-12-24
ES2350495T3 (es) 2011-01-24
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
US20140256769A1 (en) 2014-09-11
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
PT1874766E (pt) 2010-11-30
MY151075A (en) 2014-03-31
KR20070116988A (ko) 2007-12-11
JP2012153725A (ja) 2012-08-16
US20100197728A1 (en) 2010-08-05
US9126994B2 (en) 2015-09-08
EP1874766A2 (en) 2008-01-09
TWI377206B (en) 2012-11-21
AR053208A1 (es) 2007-04-25
BRPI0610657A2 (pt) 2010-07-13
HK1110866A1 (en) 2008-07-25

Similar Documents

Publication Publication Date Title
US9402840B2 (en) Crystalline form of a quinolinone-carboxamide compound
CA2561558C (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
JP2007523175A (ja) ５−ｈｔ４レセプターアゴニストとしてのインダゾール−カルボキシアミド化合物
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
EP1871772B1 (en) Quinolinone compounds as 5-ht4 receptor agonists
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
CN101312967B (zh) 作为5-ht4受体激动剂的氨基甲酸酯化合物
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound
HK1099019B (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130221

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130730

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20131022

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20131023

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20161012

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20161012

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20171013

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20171013

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20181011

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20181011

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20191010

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20191010

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20201015

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20211014

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220926

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee